This Elahere market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the increasing prevalence of platinum-resistant ovarian cancer, advancements in antibody-drug conjugate (ADC) technology, the identification of folate receptor-alpha (FRα) as a biomarker, regulatory approvals and breakthrough designations, and unmet medical needs in recurrent ovarian cancer.
Growth during the forecast period is expected to be driven by expanding clinical indications, increased adoption of personalized medicine, strategic partnerships and collaborations, rising investments in cancer research and development, and growing awareness and screening for folate receptor-alpha (FRα) expression. Key trends anticipated include the growing adoption of precision medicine, the expansion of antibody-drug conjugate (ADC) applications, a heightened focus on personalized treatment plans, increased investment in ovarian cancer research, and advancements in companion diagnostic tools.
The rising incidence of ovarian cancer is expected to drive the growth of the elahere market in the future. Ovarian cancer is a malignant disease that originates in the ovaries, fallopian tubes, or peritoneum, characterized by abnormal cell growth and the potential to spread. Contributing factors include genetic mutations such as BRCA1 and BRCA2, hormonal imbalances, age, family history, and environmental influences such as obesity and smoking. Elahere treats ovarian cancer effectively by targeting FR alpha-positive cells and delivering a cytotoxic drug directly to the tumor, minimizing harm to healthy tissue, particularly in cases of platinum-resistant ovarian cancer. For example, in 2024, the American Cancer Society, a US-based non-profit cancer advocacy organization, reported 19,680 new cases of ovarian cancer diagnosed in the US and 12,740 deaths from the disease. Thus, the increasing incidence of ovarian cancer is driving growth in the elahere market.
A key trend in the elahere market is the focus on obtaining regulatory approvals to broaden the treatment's availability for patients with platinum-resistant ovarian cancer. This approach aims to solidify its market position by offering targeted therapy to a specific patient group with advanced treatment needs. For instance, in November 2024, AbbVie, a US-based biotech company, received approval from the European Commission for Elahere as a treatment for adult patients with folate receptor-alpha (FR alpha)-positive, platinum-resistant ovarian cancer. The approval was based on positive results from the Phase III MIRASOL trial, which showed a 35% reduction in the risk of disease progression or death compared to standard chemotherapy.
In February 2024, AbbVie, a US-based biotech company, acquired ImmunoGen for $10.1 billion. This acquisition aims to enhance AbbVie’s oncology portfolio by incorporating ImmunoGen’s innovative antibody-drug conjugate (ADC) technology, particularly strengthening its capabilities in targeted cancer therapies such as Elahere. The deal is set to expand AbbVie’s pipeline in treating ovarian and other cancers, accelerating its mission to deliver more effective, precision-based treatments for patients. ImmunoGen is a US-based company specializing in the development of ADC therapeutics, including elahere.
The key company operating in the elahere market is AbbVie Inc. (ImmunoGen).
North America was the largest region in the elahere market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in elahere report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the elahere market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Elahere (mirvetuximab soravtansine-gynx) is a targeted antibody-drug conjugate (ADC) designed for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers that express high levels of folate receptor-alpha (FRalpha). It functions by delivering a cytotoxic agent directly to FRalpha-positive cancer cells, thereby minimizing damage to healthy tissues. Approved for patients who have received one to three prior lines of systemic therapy, Elahere provides a personalized treatment approach for managing advanced ovarian cancer.
The primary clinical indications in the elahere market include epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Epithelial ovarian cancer originates in the epithelial cells that form the outer layer of the ovaries. Distribution channels for Elahere include hospital pharmacies, retail pharmacies, and online pharmacies, while key end-users encompass hospitals, homecare settings, specialty centers, and others.
The elahere market research report is one of a series of new reports that provides elahere market statistics, including elahere industry global market size, regional shares, competitors with an elahere market share, detailed elahere market segments, market trends, and opportunities, and any further data you may need to thrive in the elahere industry. This elahere market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The elahere market consists of sales of antibody-drug conjugates (ADCs), companion diagnostics, and supportive oncology drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the increasing prevalence of platinum-resistant ovarian cancer, advancements in antibody-drug conjugate (ADC) technology, the identification of folate receptor-alpha (FRα) as a biomarker, regulatory approvals and breakthrough designations, and unmet medical needs in recurrent ovarian cancer.
Growth during the forecast period is expected to be driven by expanding clinical indications, increased adoption of personalized medicine, strategic partnerships and collaborations, rising investments in cancer research and development, and growing awareness and screening for folate receptor-alpha (FRα) expression. Key trends anticipated include the growing adoption of precision medicine, the expansion of antibody-drug conjugate (ADC) applications, a heightened focus on personalized treatment plans, increased investment in ovarian cancer research, and advancements in companion diagnostic tools.
The rising incidence of ovarian cancer is expected to drive the growth of the elahere market in the future. Ovarian cancer is a malignant disease that originates in the ovaries, fallopian tubes, or peritoneum, characterized by abnormal cell growth and the potential to spread. Contributing factors include genetic mutations such as BRCA1 and BRCA2, hormonal imbalances, age, family history, and environmental influences such as obesity and smoking. Elahere treats ovarian cancer effectively by targeting FR alpha-positive cells and delivering a cytotoxic drug directly to the tumor, minimizing harm to healthy tissue, particularly in cases of platinum-resistant ovarian cancer. For example, in 2024, the American Cancer Society, a US-based non-profit cancer advocacy organization, reported 19,680 new cases of ovarian cancer diagnosed in the US and 12,740 deaths from the disease. Thus, the increasing incidence of ovarian cancer is driving growth in the elahere market.
A key trend in the elahere market is the focus on obtaining regulatory approvals to broaden the treatment's availability for patients with platinum-resistant ovarian cancer. This approach aims to solidify its market position by offering targeted therapy to a specific patient group with advanced treatment needs. For instance, in November 2024, AbbVie, a US-based biotech company, received approval from the European Commission for Elahere as a treatment for adult patients with folate receptor-alpha (FR alpha)-positive, platinum-resistant ovarian cancer. The approval was based on positive results from the Phase III MIRASOL trial, which showed a 35% reduction in the risk of disease progression or death compared to standard chemotherapy.
In February 2024, AbbVie, a US-based biotech company, acquired ImmunoGen for $10.1 billion. This acquisition aims to enhance AbbVie’s oncology portfolio by incorporating ImmunoGen’s innovative antibody-drug conjugate (ADC) technology, particularly strengthening its capabilities in targeted cancer therapies such as Elahere. The deal is set to expand AbbVie’s pipeline in treating ovarian and other cancers, accelerating its mission to deliver more effective, precision-based treatments for patients. ImmunoGen is a US-based company specializing in the development of ADC therapeutics, including elahere.
The key company operating in the elahere market is AbbVie Inc. (ImmunoGen).
North America was the largest region in the elahere market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in elahere report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the elahere market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Elahere (mirvetuximab soravtansine-gynx) is a targeted antibody-drug conjugate (ADC) designed for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers that express high levels of folate receptor-alpha (FRalpha). It functions by delivering a cytotoxic agent directly to FRalpha-positive cancer cells, thereby minimizing damage to healthy tissues. Approved for patients who have received one to three prior lines of systemic therapy, Elahere provides a personalized treatment approach for managing advanced ovarian cancer.
The primary clinical indications in the elahere market include epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Epithelial ovarian cancer originates in the epithelial cells that form the outer layer of the ovaries. Distribution channels for Elahere include hospital pharmacies, retail pharmacies, and online pharmacies, while key end-users encompass hospitals, homecare settings, specialty centers, and others.
The elahere market research report is one of a series of new reports that provides elahere market statistics, including elahere industry global market size, regional shares, competitors with an elahere market share, detailed elahere market segments, market trends, and opportunities, and any further data you may need to thrive in the elahere industry. This elahere market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The elahere market consists of sales of antibody-drug conjugates (ADCs), companion diagnostics, and supportive oncology drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Elahere Market Characteristics4. Elahere Market Trends and Strategies5. Elahere Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Elahere Pricing Analysis & Forecasts30. Global Elahere Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Elahere Market32. Recent Developments in the Elahere Market
3. Elahere Market Biologic Drug Characteristics
6. Global Elahere Growth Analysis and Strategic Analysis Framework
8. Elahere Market Segmentation
9. Global Elahere Epidemiology of Clinical Indications
10. Elahere Market Regional and Country Analysis
11. Asia-Pacific Elahere Market
12. China Elahere Market
13. India Elahere Market
14. Japan Elahere Market
15. Australia Elahere Market
16. South Korea Elahere Market
17. Western Europe Elahere Market
18. UK Elahere Market
19. Germany Elahere Market
20. France Elahere Market
21. Eastern Europe Elahere Market
22. North America Elahere Market
23. USA Elahere Market
24. Canada Elahere Market
25. South America Elahere Market
26. Middle East Elahere Market
27. Africa Elahere Market
28. Elahere Market Competitive Landscape and Company Profiles
29. Global Elahere Market Pipeline Analysis
33. Elahere Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Elahere Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on elahere market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for elahere? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The elahere market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Clinical Indication: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer2) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) by End-Users: Hospitals; Homecare; Specialty Centres; Other End-Users
Key Companies Mentioned: AbbVie Inc. (ImmunoGen)
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- AbbVie Inc. (ImmunoGen)
